COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
Independent opinion of independent directors of the fifth board of directors of Jilin Zixin Pharmaceutical Co., Ltd.
According to the China Securities Regulatory Commission's "Guiding Opinions on Establishing an Independent Director System in Listed Companies", the Shenzhen Stock Exchange's "Stock Listing Rules" and the "Articles of Association", we act as Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as " The independent director of the company" carefully reviewed the proposal of the 13th meeting of the fifth board of directors of the company on the nomination of non-independent directors of the fifth board of directors. The independent opinions are as follows:
The nomination, voting and election procedures of the directors of the fifth board of directors of the company are in compliance with relevant laws and regulations and the Articles of Association. After reviewing the materials of Mr. Zhang Zhongwei, Ms. Li Baozhi and Ms. Zhong Yunxiang, the company law was not found. Article 147 shall not be held as a director of the company, nor shall it be determined by the China Securities Regulatory Commission as a market banned person and the ban shall not be lifted. The qualifications of the company are in conformity with the conditions for holding the directors of the listed company, and its educational background and experience. Professional competence and professionalism are competent for the elected positions.
We agree to nominate the by-elections of Mr. Zhang Zhongwei, Ms. Li Baozhi and Ms. Zhong Yunxiang as non-independent directors of the fifth board of directors of the company. And submitted to the second extraordinary shareholders meeting in 2014 to consider related matters.
Signature of independent director:
Fu Wei Li Fei Wang Xu
March 26, 2014